Tango Therapeutics (TNGX) Depreciation & Amortization (CF) (2020 - 2026)

Tango Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $500000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 16.67% year-over-year to $500000.0 in Q1 2026; TTM through Mar 2026 was $2.2 million, a 12.76% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 8.76% from the prior year.
• Depreciation & Amortization (CF) grew to $500000.0 in Q1 2026 per TNGX's latest filing, from $479000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $657000.0 in Q2 2024 and bottomed at $300000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $600000.0 (2023), against an average of $547294.1.
• Across the five-year window, Depreciation & Amortization (CF) surged 120.08% in 2022 and fell 20.17% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $570000.0 in 2022, then increased by 8.25% to $617000.0 in 2023, then slipped by 2.76% to $600000.0 in 2024, then decreased by 20.17% to $479000.0 in 2025, then grew by 4.38% to $500000.0 in 2026.
• Per Business Quant, the three latest TNGX Depreciation & Amortization (CF) figures stand at $500000.0 (Q1 2026), $479000.0 (Q4 2025), and $602000.0 (Q3 2025).